Artisan Small Cap Fund cites Twist Bioscience’s strong results and AI-driven demand as key drivers of outperformance in Q2 2026.
Twist Bioscience (TWST) surged in the second quarter of 2026, driven by robust earnings and rising demand for AI-powered drug discovery. The stock was highlighted by Artisan Small Cap Fund as a standout performer amid broader market gains.
The Russell 2000 Growth Index rose 25.7% in Q2, while Artisan’s Investor, Advisor, and Institutional classes returned 26.02%, 26.05%, and 26.11%, respectively. Health care led sector contributions, while technology and software faced headwinds despite strong fundamentals.
The fund remains optimistic on small-cap opportunities and AI infrastructure but has reduced exposure to software due to valuation concerns and competitive risks.